Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Amedisys reported revenue of $570.79 million for Q4 2023, a year-over-year increase of 1.6% and an EPS of $0.94, down from $1.16 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $564.85 million by 1.05%, while the EPS fell short of the consensus estimate of $1.04 by 9.62% [1] Revenue Breakdown - Net Service Revenue from Home Health was $358.90 million, surpassing the average estimate of $356.95 million, reflecting a year-over-year increase of 4.8% [2] - Net Service Revenue from High Acuity Care was $5.90 million, matching the average estimate of $4.90 million, with no year-over-year change [2] - Net Service Revenue from Hospice reached $206 million, exceeding the average estimate of $200.35 million, representing a year-over-year increase of 4.3% [2] Stock Performance - Amedisys shares have returned -1.1% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3% [2] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [2]